1.91 USD
-0.02 (-1.04%)
1.94 USD
+0.03 (+1.57%)
Overall DRRX gets a fundamental rating of 2 out of 10. We evaluated DRRX against 191 industry peers in the Pharmaceuticals industry. The financial health of DRRX is average, but there are quite some concerns on its profitability. DRRX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year DRRX has reported negative net income.
DRRX had a negative operating cash flow in the past year.
DRRX had negative earnings in each of the past 5 years.
In the past 5 years DRRX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of DRRX (-27.86%) is comparable to the rest of the industry.
The Return On Equity of DRRX (-99.86%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| ROIC | N/A |
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of DRRX (62.60%) is better than 70.56% of its industry peers.
DRRX's Gross Margin has been stable in the last couple of years.
DRRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.6% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
2. Health
2.1 Basic Checks
DRRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DRRX has been increased compared to 1 year ago.
Compared to 5 years ago, DRRX has more shares outstanding
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -67.96, we must say that DRRX is in the distress zone and has some risk of bankruptcy.
DRRX's Altman-Z score of -67.96 is on the low side compared to the rest of the industry. DRRX is outperformed by 92.39% of its industry peers.
DRRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67.96 |
ROIC/WACCN/A
WACC10.88%
2.3 Liquidity
A Current Ratio of 0.98 indicates that DRRX may have some problems paying its short term obligations.
The Current ratio of DRRX (0.98) is worse than 80.71% of its industry peers.
A Quick Ratio of 0.95 indicates that DRRX may have some problems paying its short term obligations.
With a Quick ratio value of 0.95, DRRX is not doing good in the industry: 74.62% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.95 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 83.61% over the past year.
The Revenue for DRRX has decreased by -62.89% in the past year. This is quite bad
Measured over the past years, DRRX shows a very negative growth in Revenue. The Revenue has been decreasing by -39.51% on average per year.
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
3.2 Future
Based on estimates for the next years, DRRX will show a very strong growth in Earnings Per Share. The EPS will grow by 60.95% on average per year.
DRRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 53.91% yearly.
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for DRRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DRRX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
DRRX's earnings are expected to grow with 57.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
5. Dividend
5.1 Amount
No dividends for DRRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.91
-0.02 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners22.34%
Inst Owner Change-95.74%
Ins Owners11.82%
Ins Owner Change-0.75%
Market Cap59.31M
Revenue(TTM)3.12M
Net Income(TTM)-3.48M
Analysts45.71
Price Target2.55 (33.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)16.78%
Min EPS beat(2)-9.24%
Max EPS beat(2)42.81%
EPS beat(4)3
Avg EPS beat(4)391.47%
Min EPS beat(4)-9.24%
Max EPS beat(4)1511.48%
EPS beat(8)6
Avg EPS beat(8)215.39%
EPS beat(12)10
Avg EPS beat(12)147.91%
EPS beat(16)13
Avg EPS beat(16)114.43%
Revenue beat(2)2
Avg Revenue beat(2)24.63%
Min Revenue beat(2)7.9%
Max Revenue beat(2)41.37%
Revenue beat(4)2
Avg Revenue beat(4)-9.47%
Min Revenue beat(4)-82.8%
Max Revenue beat(4)41.37%
Revenue beat(8)3
Avg Revenue beat(8)-13.96%
Revenue beat(12)3
Avg Revenue beat(12)-15.73%
Revenue beat(16)5
Avg Revenue beat(16)-0.21%
PT rev (1m)0%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.43%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)50%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 19.01 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 17.03 | ||
| P/tB | 78.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0.1
BVpS0.11
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.86% | ||
| ROE | -99.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.6% | ||
| FCFM | N/A |
ROA(3y)-55.09%
ROA(5y)-41.09%
ROE(3y)-139.78%
ROE(5y)-96.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.8%
GM growth 5Y0.25%
F-Score3
Asset Turnover0.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.65% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.95 | ||
| Altman-Z | -67.96 |
F-Score3
WACC10.88%
ROIC/WACCN/A
Cap/Depr(3y)86.47%
Cap/Depr(5y)78.99%
Cap/Sales(3y)0.86%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.67%
EPS Next Y-105.89%
EPS Next 2Y-24.45%
EPS Next 3Y57.26%
EPS Next 5Y60.95%
Revenue 1Y (TTM)-62.89%
Revenue growth 3Y-47.43%
Revenue growth 5Y-39.51%
Sales Q2Q%-79.41%
Revenue Next Year-92.31%
Revenue Next 2Y-22.88%
Revenue Next 3Y45.1%
Revenue Next 5Y53.91%
EBIT growth 1Y32.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y52.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.28%
OCF growth 3YN/A
OCF growth 5YN/A
DURECT CORPORATION / DRRX FAQ
Can you provide the ChartMill fundamental rating for DURECT CORPORATION?
ChartMill assigns a fundamental rating of 2 / 10 to DRRX.
What is the valuation status of DURECT CORPORATION (DRRX) stock?
ChartMill assigns a valuation rating of 1 / 10 to DURECT CORPORATION (DRRX). This can be considered as Overvalued.
How profitable is DURECT CORPORATION (DRRX) stock?
DURECT CORPORATION (DRRX) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for DRRX stock?
The Earnings per Share (EPS) of DURECT CORPORATION (DRRX) is expected to decline by -105.89% in the next year.